Research Analysts Offer Predictions for STOK FY2025 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Analysts at Cantor Fitzgerald dropped their FY2025 EPS estimates for Stoke Therapeutics in a report released on Thursday, June 12th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will post earnings of ($0.34) per share for the year, down from their previous estimate of $0.03. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.01) per share. Cantor Fitzgerald also issued estimates for Stoke Therapeutics' FY2026 earnings at ($3.36) EPS.

A number of other equities research analysts have also recently issued reports on the stock. Needham & Company LLC reissued a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday, April 9th. HC Wainwright lowered their price target on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $23.20.

Stoke Therapeutics Stock Performance

NASDAQ STOK traded down $0.09 on Monday, hitting $11.57. 444,834 shares of the stock traded hands, compared to its average volume of 696,959. The business's fifty day moving average is $9.62 and its two-hundred day moving average is $9.65. Stoke Therapeutics has a 12 month low of $5.35 and a 12 month high of $16.15. The firm has a market capitalization of $631.72 million, a price-to-earnings ratio of 14.65 and a beta of 1.09.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a net margin of 26.33% and a return on equity of 19.08%. The firm had revenue of $22.61 million for the quarter, compared to analysts' expectations of $4.20 million.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Siren L.L.C. lifted its position in Stoke Therapeutics by 12.4% in the 1st quarter. Siren L.L.C. now owns 2,247,347 shares of the company's stock worth $14,945,000 after buying an additional 247,347 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of Stoke Therapeutics by 125.2% in the 1st quarter. Jane Street Group LLC now owns 26,978 shares of the company's stock worth $179,000 after acquiring an additional 15,001 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Stoke Therapeutics by 21.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company's stock valued at $11,053,000 after purchasing an additional 293,072 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Stoke Therapeutics by 5.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company's stock valued at $162,000 after purchasing an additional 1,149 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new position in shares of Stoke Therapeutics during the 1st quarter valued at $2,376,000.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 6,471 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total transaction of $64,904.13. Following the completion of the sale, the insider now directly owns 25,782 shares in the company, valued at $258,593.46. The trade was a 20.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 9.50% of the stock is owned by insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.